Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Amgen has licensed RNAi drug and subcutaneous drug delivery technology from Arrowhead Pharmaceuticals for cardiovascular disease. The big biotech firm will pay Arrowhead $35 million up front, $22 million in an equity investment, and up to $617 million in option and milestone payments. The deal includes Arrowhead’s RNAi ARC-LPA program, which brings molecules designed to reduce elevated lipoprotein(a), a risk factor for heart disease.
This article has been sent to the following recipient: